Dr Reddys Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Dr Reddys Laboratories has allotted 12,100 equity shares under ESOS on 05 June 2026. With this allotment, the paid up equity share capital has increased to Rs 83,46,70,070 /-.

Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1274.9, down 1.2% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.36% on the day, quoting at 23467.1. The Sensex is at 74624.13, up 0.48%.Dr Reddys Laboratories Ltd has lost around 0.96% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 1.87% in last one month and is currently quoting at 24214.25, down 1.23% on the day. The volume in the stock stood at 12.03 lakh shares today, compared to the daily average of 26.7 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1284, down 0.89% on the day. Dr Reddys Laboratories Ltd jumped 2.13% in last one year as compared to a 4.38% slide in NIFTY and a 11.99% spurt in the Nifty Pharma index.

The PE of the stock is 33.42 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval.

In Canada, Dr. Reddy's Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.

Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1268.7, down 0.1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.54% on the day, quoting at 23505.1. The Sensex is at 74897.31, up 0.45%.Dr Reddys Laboratories Ltd has gained around 4.18% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 6.93% in last one month and is currently quoting at 23840.9, up 0.63% on the day. The volume in the stock stood at 77.06 lakh shares today, compared to the daily average of 31.23 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 1269.7, up 0.13% on the day. Dr Reddys Laboratories Ltd jumped 3.99% in last one year as compared to a 4.71% slide in NIFTY and a 11.69% spurt in the Nifty Pharma index.

The PE of the stock is 22.85 based on TTM earnings ending December 25.

Powered by Capital Market - Live News